Stenabolic

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

SR-9009 has no FDA approval, IND, or NDA. It is not a scheduled controlled substance under the CSA but may not be sold for human consumption. It is lawfully sold as a research chemical for laboratory use only.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Stenabolic

Origin

SR-9009 was developed by Thomas Burris and colleagues at The Scripps Research Institute as a tool compound for pharmacological activation of REV-ERBα (NR1D1) and REV-ERBβ (NR1D2), nuclear receptors that function as core components of the mammalian circadian clock machinery. It is a fully synthetic small molecule with no natural precursor.

Registry IDs

PubChem CID

57394020

CAS

1379686-30-2

InChIKey

MMJJNHOIVCGAAP-UHFFFAOYSA-N

DrugBank

DB14013

ChEMBL

CHEMBL1961796

Molecular formula

C20H24ClN3O4S

Molar mass

437.9 g/mol

Monoisotopic

437.1176051 Da

InChIKey

MMJJNHOIVCGAAP-UHFFFAOYSA-N

Appearance

White to off-white crystalline powder

Solubility

Poorly soluble in water; soluble in DMSO and ethanol

Sequence not available in current seed.

Stability: Sensitive to prolonged light and moisture exposure; stable under recommended storage conditions

Vial sizes

null mg

Purity grades

≥98% HPLC

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• SR-9009 binds to the ligand-binding domains of REV-ERBα and REV-ERBβ with IC50 values of approximately 670 nM and 800 nM, respectively, stabilising their interaction with co-repressor complexes (including NCoR/HDAC3) and thereby enhancing transcriptional repression of REV-ERB target genes
• These targets include BMAL1, CLOCK, and genes governing lipid synthesis, gluconeogenesis, and mitochondrial biogenesis
• In rodent studies, REV-ERB activation by SR-9009 increased skeletal-muscle mitochondrial density and capacity for fatty-acid oxidation
• Subsequent work identified that certain anti-proliferative and metabolic effects of SR-9009 occur independently of REV-ERB through mechanisms that remain incompletely characterised

Pharmacokinetics (ADME)

Half-life

Approximately 4–5 hours (rodent data; no validated human PK data available)

Clearance

Not established in humans; rapid hepatic clearance inferred from short half-life in preclinical models

PK–PD note: Oral bioavailability in mice has been reported at approximately 2%; subcutaneous/intraperitoneal routes achieve substantially higher systemic exposure. No human pharmacokinetic studies have been publi…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Prasad C, Sundar IK. Regulating the Clock: REV-ERB Agonists as Promising Therapeutic Agents. GEN Biotechnol. 2023;2(2):95-97. — Narrative review (not systematic); discusses SR9009/SR9011 and newer STL1267; notes SR9009 nonspecificity and REV-ERB-independent effects.
• Wikipedia: SR9009 — Aggregator entry; cites Solt et al. 2012 (Nature) and WADA Prohibited List placement.
• Time's up for tumors — Science Translational Medicine editorial — Notes high in vivo doses (200 mg/kg) of SR9009 needed; suggests more potent agonists required for human trials.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

No controlled human safety studies exist. The primary documented human adverse event is hepatocellular drug-induced liver injury (DILI), reported in a 2025 case report (PMID 40765588) attributing idiosyncratic hepatotoxicity to SR-9009 use; the pattern is consistent with SARM-cla…

WADA status

Prohibited in-competition and out-of-competition under WADA Prohibited List S4.5 (Hormone and Metabolic Modulators) since 2016; status carried forward in the 20…

Dominant research route: Intraperitoneal (IP) injection in mice at ~100 mg/kg b.i.d. — the route used in every cited in-vivo efficacy study (Solt 2012, Woldt 2013, Sitaula 2015, Stujanna 2017, Sulli 2018).

Mice (C57BL6 and others); 100 mg/kg b.i.d. for 7–30 days across multiple preclinical studies (Solt 2012, Woldt 2013, Sitaula 2015, Stujanna 2017, Sulli 2018)

Bioavailability: IP injection bypasses first-pass metabolism; this is the route used in essentially every cited in-vivo efficacy experiment. No human PK data exist for IP.

Dominant preclinical route. The Burris/Scripps lab and downstream groups administered SR9009 intraperitoneally at ~100 mg/kg twice daily because oral exposure was inadequate. Consumer-marketing claims (endurance, fat loss, atherosclerosis) all derive from IP-dosed mouse studies, not oral human dosing.

Mice; pharmacokinetic characterization (Trump et al. J Med Chem 2013 evaluated IV dosing for the related optimized series; SR9009 itself characterized for clearance)

Bioavailability: IV used as the reference route for clearance/PK profiling. Plasma half-life in mice reported as approximately 4 hours, with clearance in under 24 h.

IV PK in rodents established that SR9009 has very high metabolic clearance and a short plasma half-life, which is the underlying reason the Scripps lab moved to optimized successor compounds (Trump 2013). No human IV data.

Mice; oral bioavailability reported ~2.2% (Solt 2012 / Trump 2013). No human oral pharmacokinetic studies.

Bioavailability: Oral bioavailability in rodents is approximately 0–2.2%; first-pass metabolism and high hepatic clearance make meaningful oral exposure difficult even at high doses. The Burris lab's own follow-up (Trump 2013) described optimized successors with ~23% oral bioavailability as the usable in-vivo probes, explicitly moving away from SR9009 for chronic oral dosing.

Oral route was studied in mice and found functionally non-viable for sustained exposure. No published in-vivo efficacy experiment for SR9009 used oral dosing. Oral-stability/absorption gap is the central pharmacokinetic limitation of the compound.

No controlled human or animal pharmacokinetic studies identified; appears only in community/lay discussion as a workaround for poor oral absorption.

Bioavailability: No peer-reviewed PK data on sublingual SR9009 absorption. Community claims of improved absorption via mucosal bypass are unsupported by cited primary literature.

Sublingual use is a community route-of-administration workaround discussed on research-chemical forums and vendor blogs; it is not described in any retrieved primary source (Solt 2012, Trump 2013, Woldt 2013). Treated as de-identified aggregate community practice, not evidence.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $0.098 · median $0.110 · p75 $0.157 · 5 researched vendors

Legit, COA-backed band: $0.090–$0.160/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$1

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor COAs advertise ≥99% purity (e.g., Umbrella Labs LC-MS ≥99%; 4-Amino-Labs HPLC/MS ≥99%). Independent aggregator Sarmxxl reports Janoshik-graded purity tiers of 92%+/94%+/96%+/98%+. SarmGuide notes 'purity varies widely across suppliers' for SR9009/SR9011.

Independent labs cited for this compound

No FDA recall or market withdrawal specifically naming SR9009/Stenabolic was found in retrieved sources. SARM-class enforcement has occurred via warning letters and import alerts, but no compound-specific recall action was located.

Buyer red-flag checklist

• Not FDA-approved for any human use; cannot be legally marketed as a dietary supplement or drug in the U.S.
• Listed on WADA Prohibited List (S4, Hormone and Metabolic Modulators) as a Rev-erbα agonist (SR9009), prohibited at all times — sanctionable AAF in WADA-code sports.
• Sold online as a 'research chemical'/'for laboratory use only' while marketed to bodybuilders for performance/physique effects.
• Purity varies widely across suppliers; vendor COAs are largely self-reported (≥99%) with limited independent verification.
• No completed human clinical trials establishing safety or efficacy; preclinical-only evidence base.
• Short half-life and volatility make standardization difficult per aggregator assessments.
• FDA has pursued criminal actions against SARM distributors class-wide.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No retrieved independent lab test (Janoshik/MZ Biolabs/Finnrick) reporting a specific SR9009 underdosing prevalence or quantitative aggregate was found. Gray-market peptide/SARM testing aggregators note underdosing is common across the category, but no SR9009-specific figure is available from retrieved primary sources.

• FDA Import Alert 66-66 ('APIs That Appear To Be Misbranded Under 502(f)(1)...') authorizes Detention Without Physical Examination of bulk active pharmaceutical ingredients that fail the 21 CFR 201.122 labeling exemption — applicable to unapproved APIs imported for non-IND/non-exempt uses. Not SR9009-specific; applies to unapproved drug substances generally. Published/updated 10/22/2024.66-66
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times (in- and out-of-competition) under S4.4.1 'Metabolic Modulators' — Rev-erbɑ agonists, e.g. SR9009, SR9011. Listed continuously since 2016.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• self-selection toward positive cycle logs
• affiliate/commerce-linked review sites dominate top results
• no human trials — all discourse is anecdotal
• dose math and cycle-protocol speculation prevalent
• sourcing recommendations often tied to vendor affiliates

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Synthetic REV-ERBα/β agonist (SR-9009) investigated in preclinical models for effects on circadian metabolism, mitochondrial biogenesis, and exercise capacity. Approximately 2 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research use only; not FDA-approved. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet